Anselamimab for localized amyloidosis lumps
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a medicine called anselamimab for people with a rare, localized form of amyloidosis (a buildup of abnormal protein) that forms a lump and has not spread to major organs. The goal is to see if the medicine can shrink or remove these deposits safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your amyloid deposits were confirmed by a biopsy (tissue sample) or special lab test.
- Your amyloid deposits can be seen on a scan (like ultrasound, CT, or MRI).
- Your amyloidosis is confined to a single area (a lump) and has NOT spread to your heart, kidneys, or liver.
- You have not had major surgery in the last 4 weeks.
- You are not eligible for or planning to have standard chemotherapy right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.